Mean value after administration of 35 d | ||||||
---|---|---|---|---|---|---|
Parameter | 111In-vinorelbine liposome | 111In-liposome | 111In-DOTA | Vinorelbine liposome | NanoX liposome | Reference range |
Blood cells | ||||||
WBCs (103/μL) | 6.83 ± 0.27 | 6.12 ± 0.21 | 7.32 ± 0.34 | 8.99 ± 1.01 | 5.62 ± 0.12 | 3.2–12.7 |
RBCs (106/μL) | 7.78 ± 0.35 | 8.23 ± 0.32 | 7.86 ± 0.73 | 8.30 ± 0.91 | 10.23 ± 0.85 | 7.0–10.1 |
HGB (g/L) | 12.30 ± 1.25 | 11.43 ± 1.31 | 12.96 ± 1.98 | 12.40 ± 1.54 | 12.53 ± 1.56 | 11.8–14.9 |
HCT | 37.50 ± 1.54 | 37.34 ± 1.97 | 38.54 ± 2.23 | 37.27 ± 2.51 | 40.31 ± 3.58 | 36.7–46.8 |
PLTs (103/μL) | 1,312.21 ± 121.12 | 1,583.45 ± 211.45 | 1,487.56 ± 119.03 | 1,433.5 ± 107.88 | 1,116.23 ± 98.76 | 766–1,657 |
Serum | ||||||
Liver function | ||||||
ALP (U/L) | 70.5 ± 4.21* | 72.27 ± 5.67* | 150.71 ± 7.96 | 89.12 ± 10.23* | 112.24 ± 12.56 | 62–209 |
Albumin (g/dL) | 2.40 ± 0.02* | 2.40 ± 0.01* | 2.81 ± 0.06 | 2.4 ± 0.01* | 2.73 ± 0.01 | 2.5–4.8 |
ALT (U/L) | 29.21 ± 1.23 | 29.89 ± 1.20 | 77.86 ± 7.33† | 37.69 ± 3.54 | 28.94 ± 2.54 | 28–132 |
AST (U/L) | 219.00 ± 42.45 | 224.12 ± 45.89 | 131.86 ± 12.41 | 227.32 ± 24.21 | 145.67 ± 19.84 | 59–247 |
Kidney function | ||||||
Creatinine (mg/dL) | 0.25 ± 0.05 | 0.23 ± 0.07 | 0.29 ± 0.01 | 0.23 ± 0.06 | 0.24 ± 0.07 | 0.2–0.8 |
BUN (mg/dL) | 17.05 ± 0.12* | 24.1 ± 0.32 | 35.29 ± 1.66* | 19.90 ± 1.21* | 27.57 ± 2.32 | 18–29 |
↵* P < 0.05.
↵† P < 0.01, are significantly different from NanoX liposome group by Student t test.
WBCs = white blood cells; RBCs = red blood cells; HGB = hemoglobin; HCT = hematocrit; PLTs = platelets; AST = aspartate aminotransferase.
Data are expressed as mean ± SE from 5 mice administered 37 MBq of 111In-vinorelbine liposomes, 111In-liposomes, 111In-DOTA, or equivalent amount of unlabeled vinorelbine liposomes.